Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients: results from the PLATelet inhibition and patient Outcomes (PLATO) study
BACKGROUND: To investigate if ticagrelor treatment and other clinical characteristics were associated with increased cystatin C concentrations and if a deterioration in estimated renal function was associated with worse outcome in patients with acute coronary syndromes (ACS). METHODS: Plasma cystati...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2012
|
| In: |
American heart journal
Year: 2012, Volume: 164, Issue: 5, Pages: 728-734 |
| ISSN: | 1097-6744 |
| DOI: | 10.1016/j.ahj.2012.08.017 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/j.ahj.2012.08.017
|
| Author Notes: | Axel Akerblom, Lars Wallentin, Agneta Siegbahn, Richard C. Becker, Andrzej Budaj, Jay Horrow, Steen Husted, Hugo Katus, Marc J. Claeys, Robert F. Storey, Nils Asenblad, and Stefan K. James |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1571809171 | ||
| 003 | DE-627 | ||
| 005 | 20220814110423.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180409s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ahj.2012.08.017 |2 doi | |
| 035 | |a (DE-627)1571809171 | ||
| 035 | |a (DE-576)501809171 | ||
| 035 | |a (DE-599)BSZ501809171 | ||
| 035 | |a (OCoLC)1341001844 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Åkerblom, Axel |e VerfasserIn |0 (DE-588)1155729072 |0 (DE-627)1017929858 |0 (DE-576)501809953 |4 aut | |
| 245 | 1 | 0 | |a Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients |b results from the PLATelet inhibition and patient Outcomes (PLATO) study |c Axel Akerblom, Lars Wallentin, Agneta Siegbahn, Richard C. Becker, Andrzej Budaj, Jay Horrow, Steen Husted, Hugo Katus, Marc J. Claeys, Robert F. Storey, Nils Asenblad, and Stefan K. James |
| 264 | 1 | |c 2012 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.04.2018 | ||
| 520 | |a BACKGROUND: To investigate if ticagrelor treatment and other clinical characteristics were associated with increased cystatin C concentrations and if a deterioration in estimated renal function was associated with worse outcome in patients with acute coronary syndromes (ACS). METHODS: Plasma cystatin C concentrations were determined within 24 hours of admission (baseline), at discharge, 1 month, and 6 months in the PLATO trial. The changes over time in relation to randomized treatment were analyzed by analysis of covariance. C-statistics and the relative Integrated Discrimination Improvement of the cystatin C concentrations regarding the primary outcome (cardiovascular death or myocardial infarction) was evaluated by multivariable analysis including background characteristics and biomarkers: N-terminal-pro-B-type natriuretic peptide and Troponin I. RESULTS: Mean cystatin C concentrations in 2133 ticagrelor- and 2162 clopidogrel-treated patients were at baseline (0.86 mg/L and 0.86 mg/L), discharge (1.01 mg/L and 0.98 mg/L) (P < .0005), 1 month (1.00 mg/L and 0.98 mg/L) (P = .12), and 6 months (1.00 mg/L and 0.99 mg/L) (P = .17), respectively. Age, heart failure, and type of ACS were major determinants of the cystatin C concentration. c Statistics and the relative Integrated Discrimination Improvement of the primary outcome for the baseline cystatin C concentration were 0.687 and 5.2%, compared to 0.684 and 4.5% at discharge (n = 4034) and 0.693 and 5.1% at one month (n = 3096), respectively. CONCLUSIONS: Mean cystatin C concentrations increased in ACS patients, most importantly determined by age. The initial greater increase in ticagrelor-treated patients was not sustained over time. Risk prediction did not improve with serial measurements of renal markers. | ||
| 650 | 4 | |a Acute Coronary Syndrome | |
| 650 | 4 | |a Adenosine | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Analysis of Variance | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Cystatin C | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Kidney | |
| 650 | 4 | |a Kidney Function Tests | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Platelet Aggregation Inhibitors | |
| 650 | 4 | |a Purinergic P2Y Receptor Antagonists | |
| 650 | 4 | |a Risk Factors | |
| 650 | 4 | |a Ticlopidine | |
| 650 | 4 | |a Treatment Outcome | |
| 700 | 1 | |a Katus, Hugo |d 1951- |e VerfasserIn |0 (DE-588)108916618 |0 (DE-627)577155040 |0 (DE-576)289625076 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American heart journal |d Amsterdam [u.a.] : Elsevier, 1925 |g 164(2012), 5, Seite 728-734 |h Online-Ressource |w (DE-627)313061718 |w (DE-600)2003210-9 |w (DE-576)090883500 |x 1097-6744 |7 nnas |a Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients results from the PLATelet inhibition and patient Outcomes (PLATO) study |
| 773 | 1 | 8 | |g volume:164 |g year:2012 |g number:5 |g pages:728-734 |g extent:7 |a Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients results from the PLATelet inhibition and patient Outcomes (PLATO) study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ahj.2012.08.017 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180409 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 108916618 |a Katus, Hugo |m 108916618:Katus, Hugo |d 910000 |d 910100 |e 910000PK108916618 |e 910100PK108916618 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 999 | |a KXP-PPN1571809171 |e 3005341925 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"2012"}],"relHost":[{"note":["Gesehen am 21.09.2020"],"pubHistory":["1.1925 -"],"language":["eng"],"part":{"issue":"5","extent":"7","pages":"728-734","text":"164(2012), 5, Seite 728-734","volume":"164","year":"2012"},"titleAlt":[{"title":"AHJ"}],"disp":"Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients results from the PLATelet inhibition and patient Outcomes (PLATO) studyAmerican heart journal","type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"313061718","origin":[{"publisher":"Elsevier ; Mosby","dateIssuedDisp":"1925-","dateIssuedKey":"1925","publisherPlace":"Amsterdam [u.a.] ; St. Louis, Mo."}],"title":[{"title_sort":"American heart journal","title":"American heart journal","subtitle":"AHJ"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2003210-9"],"eki":["313061718"],"issn":["1097-6744"]}}],"physDesc":[{"extent":"7 S."}],"id":{"eki":["1571809171"],"doi":["10.1016/j.ahj.2012.08.017"]},"title":[{"title_sort":"Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients","subtitle":"results from the PLATelet inhibition and patient Outcomes (PLATO) study","title":"Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 09.04.2018"],"person":[{"given":"Axel","display":"Åkerblom, Axel","role":"aut","family":"Åkerblom"},{"role":"aut","family":"Katus","given":"Hugo","display":"Katus, Hugo"}],"recId":"1571809171","name":{"displayForm":["Axel Akerblom, Lars Wallentin, Agneta Siegbahn, Richard C. Becker, Andrzej Budaj, Jay Horrow, Steen Husted, Hugo Katus, Marc J. Claeys, Robert F. Storey, Nils Asenblad, and Stefan K. James"]},"language":["eng"]} | ||
| SRT | |a AKERBLOMAXOUTCOMEAND2012 | ||